Review



pf 739  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    MedChemExpress pf 739
    ( A ) Western blots of WT and AMPKLKO hepatocytes treated with vehicle or the AMPK <t>activator</t> <t>PF-739</t> (PF). ( B ) Western blots of WT and AMPKLKO liver lysates under refeeding (RF), short-fasting (SF), and long-fasting (LF) conditions. ( C ) Western blots of WT and PTGLKO liver lysates under SF, LF, and RF conditions. ( D ) Western blots of AML12 cell lysates. Cells were transfected with WT or S 349 D CRTC2 and treated with cycloheximide (CHX) for indicated times. ( E ) Western blots and quantification of proteins from WT and PTGLKO primary hepatocytes. Cells were treated with CHX for indicated times. RalA was used as the control. ( F ) Western blots of WT primary hepatocytes treated with different doses of glucagon or cAMP. Cells were isolated from C57BL/6J mice and pretreated with vehicle or PF for 2 hours followed by glucagon or cAMP treatment for 15 minutes. ( G ) Western blots of WT hepatocytes treated with different doses of PF. ( H ) Gene expression of Nr4a3 and Pgc1a in AML12 cells treated with cAMP. AML12 cells were transfected with vector or CRTC2 and pretreated with vehicle or PF. Data were normalized to vehicle-treated vector group shown in . ( I ) Dose-response curve for the effect of cAMP on gluconeogenic gene expression in WT and AMPKLKO primary hepatocytes. n = 3 per group. Experiments were performed at least 3 times. # * $ P < 0.05; ## ** $$ P < 0.01; ### *** $$$ P < 0.001 by 1-way ANOVA and unpaired Student’s t test. * indicates comparison with vector; # indicates comparison with vector + PF; $ indicates comparison with CRTC2.
    Pf 739, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pf 739/product/MedChemExpress
    Average 94 stars, based on 2 article reviews
    pf 739 - by Bioz Stars, 2026-02
    94/100 stars

    Images

    1) Product Images from "Hepatic glycogen directly regulates gluconeogenesis through an AMPK/CRTC2 axis in mice"

    Article Title: Hepatic glycogen directly regulates gluconeogenesis through an AMPK/CRTC2 axis in mice

    Journal: The Journal of Clinical Investigation

    doi: 10.1172/JCI188363

    ( A ) Western blots of WT and AMPKLKO hepatocytes treated with vehicle or the AMPK activator PF-739 (PF). ( B ) Western blots of WT and AMPKLKO liver lysates under refeeding (RF), short-fasting (SF), and long-fasting (LF) conditions. ( C ) Western blots of WT and PTGLKO liver lysates under SF, LF, and RF conditions. ( D ) Western blots of AML12 cell lysates. Cells were transfected with WT or S 349 D CRTC2 and treated with cycloheximide (CHX) for indicated times. ( E ) Western blots and quantification of proteins from WT and PTGLKO primary hepatocytes. Cells were treated with CHX for indicated times. RalA was used as the control. ( F ) Western blots of WT primary hepatocytes treated with different doses of glucagon or cAMP. Cells were isolated from C57BL/6J mice and pretreated with vehicle or PF for 2 hours followed by glucagon or cAMP treatment for 15 minutes. ( G ) Western blots of WT hepatocytes treated with different doses of PF. ( H ) Gene expression of Nr4a3 and Pgc1a in AML12 cells treated with cAMP. AML12 cells were transfected with vector or CRTC2 and pretreated with vehicle or PF. Data were normalized to vehicle-treated vector group shown in . ( I ) Dose-response curve for the effect of cAMP on gluconeogenic gene expression in WT and AMPKLKO primary hepatocytes. n = 3 per group. Experiments were performed at least 3 times. # * $ P < 0.05; ## ** $$ P < 0.01; ### *** $$$ P < 0.001 by 1-way ANOVA and unpaired Student’s t test. * indicates comparison with vector; # indicates comparison with vector + PF; $ indicates comparison with CRTC2.
    Figure Legend Snippet: ( A ) Western blots of WT and AMPKLKO hepatocytes treated with vehicle or the AMPK activator PF-739 (PF). ( B ) Western blots of WT and AMPKLKO liver lysates under refeeding (RF), short-fasting (SF), and long-fasting (LF) conditions. ( C ) Western blots of WT and PTGLKO liver lysates under SF, LF, and RF conditions. ( D ) Western blots of AML12 cell lysates. Cells were transfected with WT or S 349 D CRTC2 and treated with cycloheximide (CHX) for indicated times. ( E ) Western blots and quantification of proteins from WT and PTGLKO primary hepatocytes. Cells were treated with CHX for indicated times. RalA was used as the control. ( F ) Western blots of WT primary hepatocytes treated with different doses of glucagon or cAMP. Cells were isolated from C57BL/6J mice and pretreated with vehicle or PF for 2 hours followed by glucagon or cAMP treatment for 15 minutes. ( G ) Western blots of WT hepatocytes treated with different doses of PF. ( H ) Gene expression of Nr4a3 and Pgc1a in AML12 cells treated with cAMP. AML12 cells were transfected with vector or CRTC2 and pretreated with vehicle or PF. Data were normalized to vehicle-treated vector group shown in . ( I ) Dose-response curve for the effect of cAMP on gluconeogenic gene expression in WT and AMPKLKO primary hepatocytes. n = 3 per group. Experiments were performed at least 3 times. # * $ P < 0.05; ## ** $$ P < 0.01; ### *** $$$ P < 0.001 by 1-way ANOVA and unpaired Student’s t test. * indicates comparison with vector; # indicates comparison with vector + PF; $ indicates comparison with CRTC2.

    Techniques Used: Western Blot, Transfection, Control, Isolation, Gene Expression, Plasmid Preparation, Comparison



    Similar Products

    pf 739  (MedChemExpress)
    94
    MedChemExpress pf 739
    ( A ) Western blots of WT and AMPKLKO hepatocytes treated with vehicle or the AMPK <t>activator</t> <t>PF-739</t> (PF). ( B ) Western blots of WT and AMPKLKO liver lysates under refeeding (RF), short-fasting (SF), and long-fasting (LF) conditions. ( C ) Western blots of WT and PTGLKO liver lysates under SF, LF, and RF conditions. ( D ) Western blots of AML12 cell lysates. Cells were transfected with WT or S 349 D CRTC2 and treated with cycloheximide (CHX) for indicated times. ( E ) Western blots and quantification of proteins from WT and PTGLKO primary hepatocytes. Cells were treated with CHX for indicated times. RalA was used as the control. ( F ) Western blots of WT primary hepatocytes treated with different doses of glucagon or cAMP. Cells were isolated from C57BL/6J mice and pretreated with vehicle or PF for 2 hours followed by glucagon or cAMP treatment for 15 minutes. ( G ) Western blots of WT hepatocytes treated with different doses of PF. ( H ) Gene expression of Nr4a3 and Pgc1a in AML12 cells treated with cAMP. AML12 cells were transfected with vector or CRTC2 and pretreated with vehicle or PF. Data were normalized to vehicle-treated vector group shown in . ( I ) Dose-response curve for the effect of cAMP on gluconeogenic gene expression in WT and AMPKLKO primary hepatocytes. n = 3 per group. Experiments were performed at least 3 times. # * $ P < 0.05; ## ** $$ P < 0.01; ### *** $$$ P < 0.001 by 1-way ANOVA and unpaired Student’s t test. * indicates comparison with vector; # indicates comparison with vector + PF; $ indicates comparison with CRTC2.
    Pf 739, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pf 739/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    pf 739 - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    ( A ) Western blots of WT and AMPKLKO hepatocytes treated with vehicle or the AMPK activator PF-739 (PF). ( B ) Western blots of WT and AMPKLKO liver lysates under refeeding (RF), short-fasting (SF), and long-fasting (LF) conditions. ( C ) Western blots of WT and PTGLKO liver lysates under SF, LF, and RF conditions. ( D ) Western blots of AML12 cell lysates. Cells were transfected with WT or S 349 D CRTC2 and treated with cycloheximide (CHX) for indicated times. ( E ) Western blots and quantification of proteins from WT and PTGLKO primary hepatocytes. Cells were treated with CHX for indicated times. RalA was used as the control. ( F ) Western blots of WT primary hepatocytes treated with different doses of glucagon or cAMP. Cells were isolated from C57BL/6J mice and pretreated with vehicle or PF for 2 hours followed by glucagon or cAMP treatment for 15 minutes. ( G ) Western blots of WT hepatocytes treated with different doses of PF. ( H ) Gene expression of Nr4a3 and Pgc1a in AML12 cells treated with cAMP. AML12 cells were transfected with vector or CRTC2 and pretreated with vehicle or PF. Data were normalized to vehicle-treated vector group shown in . ( I ) Dose-response curve for the effect of cAMP on gluconeogenic gene expression in WT and AMPKLKO primary hepatocytes. n = 3 per group. Experiments were performed at least 3 times. # * $ P < 0.05; ## ** $$ P < 0.01; ### *** $$$ P < 0.001 by 1-way ANOVA and unpaired Student’s t test. * indicates comparison with vector; # indicates comparison with vector + PF; $ indicates comparison with CRTC2.

    Journal: The Journal of Clinical Investigation

    Article Title: Hepatic glycogen directly regulates gluconeogenesis through an AMPK/CRTC2 axis in mice

    doi: 10.1172/JCI188363

    Figure Lengend Snippet: ( A ) Western blots of WT and AMPKLKO hepatocytes treated with vehicle or the AMPK activator PF-739 (PF). ( B ) Western blots of WT and AMPKLKO liver lysates under refeeding (RF), short-fasting (SF), and long-fasting (LF) conditions. ( C ) Western blots of WT and PTGLKO liver lysates under SF, LF, and RF conditions. ( D ) Western blots of AML12 cell lysates. Cells were transfected with WT or S 349 D CRTC2 and treated with cycloheximide (CHX) for indicated times. ( E ) Western blots and quantification of proteins from WT and PTGLKO primary hepatocytes. Cells were treated with CHX for indicated times. RalA was used as the control. ( F ) Western blots of WT primary hepatocytes treated with different doses of glucagon or cAMP. Cells were isolated from C57BL/6J mice and pretreated with vehicle or PF for 2 hours followed by glucagon or cAMP treatment for 15 minutes. ( G ) Western blots of WT hepatocytes treated with different doses of PF. ( H ) Gene expression of Nr4a3 and Pgc1a in AML12 cells treated with cAMP. AML12 cells were transfected with vector or CRTC2 and pretreated with vehicle or PF. Data were normalized to vehicle-treated vector group shown in . ( I ) Dose-response curve for the effect of cAMP on gluconeogenic gene expression in WT and AMPKLKO primary hepatocytes. n = 3 per group. Experiments were performed at least 3 times. # * $ P < 0.05; ## ** $$ P < 0.01; ### *** $$$ P < 0.001 by 1-way ANOVA and unpaired Student’s t test. * indicates comparison with vector; # indicates comparison with vector + PF; $ indicates comparison with CRTC2.

    Article Snippet: PF-739 and Ulk1 inhibitor (SBI-0206965) were purchased from MedChem Express.

    Techniques: Western Blot, Transfection, Control, Isolation, Gene Expression, Plasmid Preparation, Comparison